AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17366357 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery disease confirmed based on history of myocardial infarction
Number of subjects: 2593
Study 17366357 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery disease confirmed based on positive electrocardiographic stress test
Number of subjects: 2593
Study 17366357 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery disease confirmed based on history of typical angina in subjects >60 years
Number of subjects: 2593
Study 17366357 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery disease confirmed based on history of previous acute coronary syndrome
Number of subjects: 2593
Study 17366357 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery disease confirmed based on PCI
Number of subjects: 2593
Study 17366357 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery disease confirmed based on CABG
Number of subjects: 2593
Study 17366357 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery disease confirmed based on positive coronary angiography
Number of subjects: 2593
Study 17366357 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with diagnosed stable CAD with normal blood pressure
Number of subjects: 2593
Study 17366357 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with normal LDL cholesterol concentrations (<3.36 mmol/L)
Number of subjects: 2593
Study 17366357 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with metabolic syndrome diagnosed according to NCEP ATP III criteria
Number of subjects: 2593
Study 17366357 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients presenting symptoms of congestive heart failure
Number of subjects: 2593
Study 17366357 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with rhythm or conduction disturbances (most commonly atrial fibrillation)
Number of subjects: 2593
Study 17366357 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with previous stroke
Number of subjects: 2593
Study 17366357 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with transient ischaemic attack
Number of subjects: 2593
Study 17366357 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with peripheral artery disease
Number of subjects: 2593
Study 17366357 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with asthma or COPD
Number of subjects: 2593
Study 16307958 — intervention group
Group type: EXPERIMENTAL
Intervention: Face targets with solitary flanking distractor face
Number of subjects: 0
Study 16307958 — intervention group
Group type: EXPERIMENTAL
Intervention: Face targets with solitary flanking nonface stimulus
Number of subjects: 0
Study 16307958 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonface targets with solitary flanking distractor face
Number of subjects: 0
Study 16307958 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonface targets with solitary flanking nonface stimulus
Number of subjects: 0
Study 16307958 — intervention group
Group type: EXPERIMENTAL
Intervention: Four task-irrelevant flankers (distractor faces)
Number of subjects: 0
Study 16307958 — intervention group
Group type: EXPERIMENTAL
Intervention: Four task-irrelevant flankers (nonface targets)
Number of subjects: 0
Study 9796505 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group with alum-containing mouthrinse
Number of subjects: 45
Study 9796505 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control group (mouthrinse without alum)
Number of subjects: 45
Study 9796505 — intervention group
Group type: COMPARATOR
Intervention: Treatment control (distilled water)
Number of subjects: 45
Study 7808281 — intervention group
Group type: EXPERIMENTAL
Intervention: Encoding enactment (motor encoding and verbal test)
Number of subjects: 0
Study 7808281 — intervention group
Group type: COMPARATOR
Intervention: Retrieval enactment (verbal encoding and motor test)
Number of subjects: 0
Study 7808281 — intervention group
Group type: COMPARATOR
Intervention: Dual enactment (motor encoding and motor test)
Number of subjects: 0
Study 2548299 — intervention group
Group type: EXPERIMENTAL
Intervention: Almitrine
Number of subjects: 12
Study 2548299 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 811319 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline 500 mg four times a day for 7 days
Number of subjects: 400
Study 811319 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline 250 mg four times a day for 14 days
Number of subjects: 400
Study 811319 — intervention group
Group type: EXPERIMENTAL
Intervention: Deteclo 300 mg three times a day for 3 weeks
Number of subjects: 400
Study 811319 — intervention group
Group type: COMPARATOR
Intervention: Tetracycline 250 mg four times a day for 4 days
Number of subjects: 400
Study 31164341 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib maintenance therapy
Number of subjects: 0
Study 31164341 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28032333 — intervention group
Group type: EXPERIMENTAL
Intervention: α1-adrenergic blockade (prazosin; 0.05 mg kg -1)
Number of subjects: 9
Study 28032333 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 25788405 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g protein supplement, 10 times weekly during 13 weeks
Number of subjects: 60
Study 24937976 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of vaginal progesterone (P) and 75 IU recombinant luteinizing hormone (rLH), 4 doses every 3 days, starting on the day of embryo transfer
Number of subjects: 47
Study 24937976 — intervention group
Group type: COMPARATOR
Intervention: Luteal vaginal progesterone (P)
Number of subjects: 47
Study 24937976 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of vaginal progesterone (P) and 75 IU recombinant luteinizing hormone (rLH)
Number of subjects: 47
Study 22193727 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine (15 mg/d for 14 days)
Number of subjects: 10
Study 22193727 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 22193727 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine
Number of subjects: 10
Study 20156958 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality review committee data
Number of subjects: 4
Study 20156958 — intervention group
Group type: COMPARATOR
Intervention: Death certificate data
Number of subjects: 4
Study 18042892 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5% (30 mL)
Number of subjects: 79
Study 18042892 — intervention group
Group type: COMPARATOR
Intervention: Placebo (isotonic saline)
Number of subjects: 79
Study 15609378 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic appendicectomy (LA)
Number of subjects: 163
Study 15609378 — intervention group
Group type: COMPARATOR
Intervention: Open appendicectomy (OA)
Number of subjects: 163
Study 14601471 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral magnesium supplementation (Slow‐Mag B6) at 320 mg/day
Number of subjects: 92
Study 14601471 — intervention group
Group type: COMPARATOR
Intervention: Control group (hypertensive patients not treated pharmacologically)
Number of subjects: 92
Study 14601471 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients treated with diuretics
Number of subjects: 92
Study 14601471 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients treated with Ca channel blockers
Number of subjects: 92
Study 14601471 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral magnesium supplementation (Slow‐Mag B6)
Number of subjects: 92
Study 10467795 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg nalbuphine
Number of subjects: 90
Study 10467795 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg nalbuphine
Number of subjects: 90
Study 10467795 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg nalbuphine
Number of subjects: 90
Study 7784339 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled release acetaminophen (paracetamol) tablet A
Number of subjects: 0
Study 7784339 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled release acetaminophen (paracetamol) tablet B
Number of subjects: 0
Study 7784339 — intervention group
Group type: COMPARATOR
Intervention: In vitro profiles at paddle speed of 10 rpm
Number of subjects: 0
Study 7784339 — intervention group
Group type: EXPERIMENTAL
Intervention: In vivo release rate in dogs
Number of subjects: 0
Study 1995718 — intervention group
Group type: EXPERIMENTAL
Intervention: rgp160 vaccine
Number of subjects: 12
Study 1995718 — intervention group
Group type: COMPARATOR
Intervention: recombinant hepatitis B vaccine
Number of subjects: 12
Study 1995718 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 6084217 — intervention group
Group type: EXPERIMENTAL
Intervention: Feeder vessel photocoagulation
Number of subjects: 0
Study 6084217 — intervention group
Group type: COMPARATOR
Intervention: Control eyes
Number of subjects: 0
Study 31028782 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromoendoscopy (CE)
Number of subjects: 246
Study 31028782 — intervention group
Group type: COMPARATOR
Intervention: Conventional white-light endoscopy (WLE)
Number of subjects: 246
Study 29684789 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipedal hopping at 60 beats/min (bpm)
Number of subjects: 13
Study 29684789 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipedal hopping at 40 bpm
Number of subjects: 13
Study 29684789 — intervention group
Group type: COMPARATOR
Intervention: Bipedal hopping at 60 bpm
Number of subjects: 13
Study 26826179 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorapaxar
Number of subjects: 3787
Study 26826179 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3787
Study 28159849 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 8
Study 28159849 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 8
Study 22963498 — intervention group
Group type: EXPERIMENTAL
Intervention: Controllable situation (knew the topic in advance)
Number of subjects: 72
Study 22963498 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncontrollable situation (impromptu speech)
Number of subjects: 72
Study 22963498 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants who believed in the benefits of worry
Number of subjects: 72
Study 20663993 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Number of subjects: 199
Study 19436745 — intervention group
Group type: EXPERIMENTAL
Intervention: Mebendazole treatment every 3 months
Number of subjects: 666
Study 19436745 — intervention group
Group type: EXPERIMENTAL
Intervention: Mebendazole treatment
Number of subjects: 666
Study 19436745 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 666
Study 16970950 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan (IRB) 300 mg per day
Number of subjects: 72
Study 16970950 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 15461606 — intervention group
Group type: EXPERIMENTAL
Intervention: Parietaria pollen vaccine
Number of subjects: 30
Study 15461606 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 30
Study 11287374 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study 11287374 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with Alzheimer's disease
Number of subjects: 0
Study 11287374 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study 9645412 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg zopiclone
Number of subjects: 40
Study 9645412 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 7562123 — intervention group
Group type: EXPERIMENTAL
Intervention: tissue plasminogen activator (tPA)
Number of subjects: 0
Study 7562123 — intervention group
Group type: COMPARATOR
Intervention: streptokinase (SK)
Number of subjects: 0
Study 2195579 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (3.5 mg/kg)
Number of subjects: 25
Study 2195579 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 110028 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% DSCG eye drops
Number of subjects: 30
Study 110028 — intervention group
Group type: COMPARATOR
Intervention: Placebo eye drops
Number of subjects: 30
Study 31418022 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 µg RSV-PreF vaccine
Number of subjects: 400
Study 31418022 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 µg RSV-PreF vaccine
Number of subjects: 400
Study 31418022 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 µg RSV-PreF vaccine
Number of subjects: 400
Study 31418022 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study 29351542 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-adhesion gel (hyaluronic acid-carboxymethylcellulose, Seprafilm®) applied locally during surgery
Number of subjects: 200
Study 29351542 — intervention group
Group type: COMPARATOR
Intervention: No anti-adhesion gel applied (control group)
Number of subjects: 200
Study 26147178 — intervention group
Group type: EXPERIMENTAL
Intervention: Illustrated leaflet and verbal instructions on oral hygiene and utilization habits
Number of subjects: 70
Study 26147178 — intervention group
Group type: COMPARATOR
Intervention: Advice to continue cleaning and wearing new dentures as previous dentures
Number of subjects: 70
Study 23369173 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational learning (visual arts)
Number of subjects: 131
Study 23369173 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational learning (verbal arts)
Number of subjects: 131
Study 23369173 — intervention group
Group type: COMPARATOR
Intervention: Control condition (learning by practicing)
Number of subjects: 131
Study 20802258 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocking-chair group (RCG, n=26)
Number of subjects: 51
Study 20802258 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG, n=25)
Number of subjects: 51
Study 19246610 — intervention group
Group type: EXPERIMENTAL
Intervention: Videoconferencing nutritional counselling (2 additional sessions at 4 and 8 weeks)
Number of subjects: 32
Study 19246610 — intervention group
Group type: COMPARATOR
Intervention: Control group (single group education session via videoconference)
Number of subjects: 32
Study 19246610 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 32
Study 16708735 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG tube feeding
Number of subjects: 22
Study 16708735 — intervention group
Group type: COMPARATOR
Intervention: NG tube feeding
Number of subjects: 22
Study 15001627 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol (E(2))
Number of subjects: 8
Study 11689582 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative chemotherapy (PeCT)
Number of subjects: 1275
Study 11689582 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant treatment
Number of subjects: 1275
Study 9113215 — intervention group
Group type: EXPERIMENTAL
Intervention: Doctors Helping Smokers (DHS) model
Number of subjects: 601
Study 9113215 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 601
Study 9113215 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 601
Study 7952453 — intervention group
Group type: EXPERIMENTAL
Intervention: Expanded polytetrafluoroethylene (ePTFE) patch
Number of subjects: 20
Study 7952453 — intervention group
Group type: COMPARATOR
Intervention: Braided polyester tape
Number of subjects: 20
Study 2356405 — intervention group
Group type: EXPERIMENTAL
Intervention: Nycotest‐Chrom (N‐test)
Number of subjects: 110
Study 2356405 — intervention group
Group type: EXPERIMENTAL
Intervention: Thromboquant‐PT (Tbq)
Number of subjects: 110
Study 2356405 — intervention group
Group type: COMPARATOR
Intervention: Thrombotest (TT)
Number of subjects: 110
Study 363486 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisuride hydrogen maleate
Number of subjects: 240
Study 363486 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 31797385 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial stimulation intervention with weekly home visits for 18 months
Number of subjects: 421
Study 31650270 — intervention group
Group type: EXPERIMENTAL
Intervention: Limbal conjunctival autograft (LCAU)
Number of subjects: 40
Study 31650270 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative mitomycin C (MMC) 0.02% for 5 min
Number of subjects: 40
Study 31650270 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined LCAU + MMC 0.02% for 5 min
Number of subjects: 40
Study 28623848 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking-reduction intervention (SRI)
Number of subjects: 369
Study 28623848 — intervention group
Group type: COMPARATOR
Intervention: Exercise and diet advice (EDA) control
Number of subjects: 369
Study 25688159 — intervention group
Group type: EXPERIMENTAL
Intervention: anti‐CD3 × anti‐HER2 bispecific antibody (HER2Bi) armed anti‐CD3‐activated T cells (aATC)
Number of subjects: 23
Study 23778295 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual segmental FJ provocation tests (spinal percussion, springing, and segmental rotation tests) in subjects with LBP
Number of subjects: 150
Study 23778295 — intervention group
Group type: COMPARATOR
Intervention: Manual segmental FJ provocation tests (spinal percussion, springing, and segmental rotation tests) in control subjects
Number of subjects: 150
Study 23778295 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI findings of effusion and/or edema in subjects with LBP
Number of subjects: 150
Study 23778295 — intervention group
Group type: COMPARATOR
Intervention: MRI findings of effusion and/or edema in control subjects
Number of subjects: 150
Study 23778295 — intervention group
Group type: EXPERIMENTAL
Intervention: True-positive findings in subjects with LBP
Number of subjects: 150
Study 23778295 — intervention group
Group type: COMPARATOR
Intervention: True-positive findings in control subjects
Number of subjects: 150
Study 21612140 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute Normovolemic Hemodilution (ANH) group
Number of subjects: 40
Study 21612140 — intervention group
Group type: COMPARATOR
Intervention: Control group (homologous blood transfusion)
Number of subjects: 40
Study 21612140 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 19275276 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal oxybutynin 3.9 mg/day
Number of subjects: 0
Study 19275276 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal oxybutynin
Number of subjects: 0
Study 19275276 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16717329 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (250 mg infusion)
Number of subjects: 7
Study 16717329 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline infusion)
Number of subjects: 7
Study 16717329 — intervention group
Group type: COMPARATOR
Intervention: Control (saline infusion with 37 degrees C water immersion)
Number of subjects: 7
Study 17115498 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 11322410 — intervention group
Group type: EXPERIMENTAL
Intervention: Bare-sclera procedure (group 1)
Number of subjects: 38
Study 11322410 — intervention group
Group type: EXPERIMENTAL
Intervention: Bare-sclera with intraoperative mitomycin C (MMC 0.02% for 30 seconds; group 2)
Number of subjects: 38
Study 11322410 — intervention group
Group type: EXPERIMENTAL
Intervention: Pterygium excision with conjunctival autografting (group 3)
Number of subjects: 38
Study 11322410 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy fellow eyes and seven age- and sex-matched subjects)
Number of subjects: 38
Study 9399764 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide 50 microg s.c. t.i.d (n = 6)
Number of subjects: 12
Study 9399764 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 6)
Number of subjects: 12
Study 8421972 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive strategy
Number of subjects: 3339
Study 8421972 — intervention group
Group type: COMPARATOR
Intervention: Conservative strategy
Number of subjects: 3339
Study 8421972 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who did not perform the predischarge exercise test
Number of subjects: 3339
Study 8421972 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who performed the predischarge exercise test
Number of subjects: 3339
Study 8421972 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative strategy with exercise-induced ST-segment depression or chest pain
Number of subjects: 3339
Study 3548811 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin (12 mg single dose on day 1, followed by placebo for 7 days)
Number of subjects: 59
Study 3548811 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine (DEC, total dose 1.3 g)
Number of subjects: 59
Study 3548811 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 29762818 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium Alloy (TiA) miniscrews
Number of subjects: 15
Study 29762818 — intervention group
Group type: COMPARATOR
Intervention: Stainless Steel (SS) miniscrews
Number of subjects: 15
Study 25880893 — intervention group
Group type: EXPERIMENTAL
Intervention: Reused phaco tip in torsional phacoemulsification
Number of subjects: 136
Study 25880893 — intervention group
Group type: COMPARATOR
Intervention: Single use phaco tip in torsional phacoemulsification
Number of subjects: 136
Study 25880893 — intervention group
Group type: EXPERIMENTAL
Intervention: Reused phaco tip in transversal phacoemulsification
Number of subjects: 136
Study 25880893 — intervention group
Group type: COMPARATOR
Intervention: Single use phaco tip in transversal phacoemulsification
Number of subjects: 136
Study 25880893 — intervention group
Group type: EXPERIMENTAL
Intervention: Both tip groups in torsional and transversal phacoemulsification
Number of subjects: 136
Study 24745637 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-lasting permethrin impregnated uniforms
Number of subjects: 159
Study 24745637 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment uniforms (Control)
Number of subjects: 159
Study 24308874 — intervention group
Group type: EXPERIMENTAL
Intervention: New evidence-based smoking cessation service package
Number of subjects: 440
Study 24308874 — intervention group
Group type: COMPARATOR
Intervention: Routine service package (5A approach)
Number of subjects: 440